Study Overview
Sex: All
Age: 18 Years / 75 Years
No Study Documents
Study Overview
Sex: All
Age: 18 Years / 75 Years
No Study Documents
Active, not recruiting
Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Chemoradiotherapy in Participant With ESCC
Sex: All
Age: 18 Years / 75 Years
No Study Documents
Sex: All
Age: 18 Years / 75 Years
No Study Documents